IMPACT OF THE USE OF BIOLOGICS AND THEIR DISCONTINUATION ON THE GUT MICROBIOTA OF PSORIASIS PATIENTS

DEI-CAS IGNACIO; ROSSO AYELÉN; GILIBERTO FLORENCIA; PENAS-STEINHARDT ALBERTO

Congreso; 31ST CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) 2022; 2022

Impact of the use of biologics and their discontinuation on the gut microbiota of psoriasis patients.METHODS: We evaluated 27 non-Ps-Controls and 86 Ps-patients, these include 28 Mild-Psoriasis, 27 Severe-Psoriasis, 19 Treated-Patients and 12 Washout-Medication. These are from metropolitan area of Buenos Aires, Argentina. Fecal DNA was extracted by PowerFecal DNA Isolation Kit Qiagen and hypervariable regions V3-V4 of the bacterial 16SR-gene were sequenced using a MiSeq-Platform. Sequences were analyzed with the QIIME2 environment. Differential functional pathways were evaluated using PICRUSt, in addition compositional analysis of microbiomes (ANCOM) were observed between patient groups and subgroups.Title: Authors: Dei-Cas Ignacio1, Rosso Ayelén, Giliberto Florencia2, Penas-Steinhardt Alberto3.Author information:1.Psoriasis BsAs. Buenos Aires, Argentina2.Laboratorio de Distrofinopatías, Facultad de Farmacia y Bioquímica-UBA INIGEM, CONICET-Universidad de Buenos Aires, Argentina3.Laboratorio de Genómica Computacional, Dto. Ciencias Básicas-Universidad Nacional de Luján, Argentina Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, ArgentinaLaboratorio de Genómica Computacional (GEC-UNLu), Departamento de Ciencias Básicas, Universidad Nacional de Luján, Luján, ArgentinaIntroduction: Increasing number of studies have shown that the imbalance of gut microbial populations or dysbiosis may be implicated in psoriasis pathogenesis. Recent studies suggest that psoriasis treatment can shift the abundance of specific taxa, however the effect of treatment discontinuation on gut microbiota has not been investigated. The aim of this study was to investigate whether there were differences in gut microbiota in psoriasis patients treated with secukinumab compared to controls, non-treated psoriasis patients and after 3 months of drug discontinuation (discontinuation group). Patients and methods:We evaluated 27 non-psoriasis and 86 psoriasis fecal samples (28 mild psoriasis, 27 moderate to severe psoriasis, 19 secukinumab treated patients and 12 drug discontinuation). Fecal microbial diversity and composition were analyzed using the Illumina MiSeq sequencing platform by targeting the hypervariable V3-V4 regions of the 16S rRNA gene. Bioinformatic analysis was performed. Results: Secukinumab-treated patients showed higher biodiversity (Shannon index) and observed OTUs than moderate-to-severe psoriasis patients and controls. We found no differences in beta diversity between groups (weighted and unweighted Unifrac). When comparing the major genera detected (ANCOM), we found that secukinumab-treated patients differed from controls without psoriasis in Marvinbryantia abundance (p < 0.05). Samples taken after treatment discontinuation showed lower alpha diversity compared to samples under secukinumab treatment, although the difference was not statistically significant. Genera Brevundimonas was overexpressed in the discontinuation group compared to non-treated psoriasis patients. Finally, differential functional pathways were evaluated using PICRUSt, showing patients drug discontinuation having capacity for glycogen degradation when compared to psoriasis patients. Conclusion: Secukinumab increased the biodiversity of the gut microbiota and promoted shifts in the abundance of specific taxa, tended to disappear after treatment discontinuation. Therefore, the role of biologics on the gut microbiota of psoriasis patients deserves further study.